Innovative Treatment Eliminates Cancer Cells While Preserving Healthy Tissue

Researchers at the University of Geneva have developed innovative CAR-T cells that specifically target the PTPRZ1 marker on glioblastoma cells, a significant advancement in cancer treatment, SciTech Daily reported yesterday.

This engineered immune therapy not only attacks marked tumor cells but also effectively identifies unmarked ones while sparing healthy tissue. Glioblastoma, the most aggressive primary brain tumor, has a dismal average survival rate of less than two years with current treatments.

In preclinical trials, these CAR-T cells successfully prolonged the lives of mice without causing toxicity. The study’s lead, Denis Migliorini, emphasized the importance of the PTPRZ1 marker in creating these targeted therapies. Unlike traditional methods, this approach uses messenger RNA to produce the antibodies needed for targeting tumors, offering a flexible treatment platform. The promising results pave the way for upcoming clinical trials in humans, potentially revolutionizing treatment for this challenging cancer.